Evidence of Mpox Virus Infection Among Persons Without Characteristic Lesions or Rash Presenting for First Dose of JYNNEOS Vaccine-District of Columbia, August 2022.

Yasmin P Ogale, Nicolle Baird,Michael B Townsend,Isha Berry, Isabel Griffin,Michelle Lee, Patrick Ashley, Trevor Rhodes, Tiffany Notigan,Nhien Wynn,Chantal Kling,Todd Smith,Lalita Priyamvada,William C Carson, Terese Navarra,Patrick Dawson,Paul J Weidle, Christina Willut, Anil T Mangla,Panayampalli S Satheshkumar,Christina L Hutson,David A Jackson,Michelle A Waltenburg, DC Mpox Response Project Team

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2023）

引用 4|浏览8

暂无评分

摘要

We assessed mpox virus prevalence in blood, pharyngeal, and rectal specimens among persons without characteristic rash presenting for JYNNEOS vaccine. Our data indicate that the utility of risk-based screening for mpox in persons without skin lesions or rash via pharyngeal swabs, rectal swabs, and/or blood is likely limited.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要